Crypreserved ampule of Peripheral Blood Human Natural Killer Cells (CD56 negative immunomagnetic selection) containing ≥ 5 million cells
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 10 million cells
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 25 million cells
For efficient transfection of primary NK (natural killer) cells in the Nucleofector® I/II/2b System
Cryopreserved human leukapheresis product (≥9.5 billion cells)
Cryopreserved human leukapheresis product (≥5.0 billion cells)
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 50 million cells with population frequency information
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 100 million cells with cell type frequency information
-
Application ExampleAnalysis of undirected migration of NK cells
-
Undirected Migration Assay of NK Cells -
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
NK-92 Transfection Protocol - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of NK-92 cells with the Cell Line Nucleofector™ Kit R
-
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay -
Predicting Antibody Dependent Cell-Mediated Cytotoxicity (ADCC)Genotypic and Phenotypic Screening of Human Peripheral Blood Mononuclear Cells
-
Genome Editing using Nucleofector® Technology – Citation ListSelected citations for genome editing using ZFN, TALEN or CRISPR/Cas9 or transposition systems (e.g. for CAR-T) in combination with Lonza's Nucleofector® Technology.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)